Breaking News Instant updates and real-time market news.

HAE

Haemonetics

$34.77

-1.35 (-3.74%)

10:33
10/14/16
10/14
10:33
10/14/16
10:33

Haemonetics initiated with a Sell rating at Off Wall Street

  • 07

    Nov

HAE Haemonetics
$34.77

-1.35 (-3.74%)

05/16/16
GSCO
05/16/16
UPGRADE
Target $29
GSCO
Neutral
Haemonetics upgraded to Neutral from Sell at Goldman
Goldman Sachs analyst David Roman upgraded Haemonetics to Neutral saying the risk/reward is more balanced with consensus numbers and management expectations "rebased." The analyst raised his price target for the shares to $29 from $25.
05/16/16
05/16/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. J.C. Penney (JCP) upgraded to Outperform from Neutral at Baird by analyst Mark Altschwager, who said the stock's current risk/reward profile is attractive with a credible turnaround story unfolding at the retailer. The analyst also said management's financial targets are achievable despite secular pressures impacting the industry. 2. CB&I (CBI) upgraded to Buy at Johnson Rice as the firm believes the valuation gap between the stock and those of its peers should narrow as investors gain confidence in CB&I's cash generation and declining debt levels. 3. Vornado (VNO) upgraded to Buy at Evercore ISI by analyst Steve Sakwa, who sees catalysts ahead that include cash income that is set to contribute to the P&L from Q2 thru early 2018. 4. Haemonetics (HAE) upgraded to Neutral at Goldman with analyst David Roman saying the risk/reward is more balanced with consensus numbers and management expectations "rebased." 5. Nokia (NOK) upgraded to Buy at Canaccord citing a positive long-term risk/reward. The firm sees Nokia positioned for better execution and said it will create shareholder value through restructuring and improved synergies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/03/16
BRRR
08/03/16
DOWNGRADE
BRRR
Market Perform
Haemonetics downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Haemonetics to Market Perform saying upside looks limited following the company's Q1 results. The analyst believes the stock's risk/reward no longer favors investment.
08/15/16
SIDC
08/15/16
DOWNGRADE
Target $39
SIDC
Neutral
Haemonetics downgraded to Neutral from Buy at Sidoti
Sidoti analyst James Sidoti downgraded Haemonetics to Neutral citing valuation with the shares near his unchanged price target of $39.

TODAY'S FREE FLY STORIES

AMGN

Amgen

$173.14

-0.15 (-0.09%)

16:01
02/21/17
02/21
16:01
02/21/17
16:01
Hot Stocks
Amgen says Repatha gets EU approval for new single-dose option »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 09

    Mar

  • 17

    Mar

  • 21

    Mar

  • 19

    Jul

LNTH

Lantheus

, GE

General Electric

$30.57

0.195 (0.64%)

16:01
02/21/17
02/21
16:01
02/21/17
16:01
Hot Stocks
Lantheus, GE Healthcare sign term sheet for flurpiridaz development »

Lantheus Medical Imaging,…

LNTH

Lantheus

GE

General Electric

$30.57

0.195 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 26

    Apr

GBT

Global Blood Therapeutics

16:01
02/21/17
02/21
16:01
02/21/17
16:01
Syndicate
Global Blood Therapeutics files to sell $75M in common stock »

Cantor Fitzgerald &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDQ

Novadaq

$6.59

-0.01 (-0.15%)

, CI

Cigna

$146.52

2.96 (2.06%)

15:57
02/21/17
02/21
15:57
02/21/17
15:57
Hot Stocks
LifeNet says Dermacell receives coverage from Cigna »

Cigna (CI) now covers…

NVDQ

Novadaq

$6.59

-0.01 (-0.15%)

CI

Cigna

$146.52

2.96 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

  • 28

    Feb

PBYI

Puma Biotechnology

$40.25

2.9 (7.76%)

15:56
02/21/17
02/21
15:56
02/21/17
15:56
Options
Puma Biotechnology put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Jul

SODA

SodaStream

$47.14

-0.53 (-1.11%)

15:54
02/21/17
02/21
15:54
02/21/17
15:54
Hot Stocks
Teleios Capital lowers stake in SodaStream to 4.5% »

Teleios Capital has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$27.00

0.2 (0.75%)

15:48
02/21/17
02/21
15:48
02/21/17
15:48
Hot Stocks
Matrix Partners China lowers stake in Momo to 12.6% from 15.4% »

On September 23, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

BMY

Bristol-Myers

$53.55

-1.04 (-1.91%)

15:38
02/21/17
02/21
15:38
02/21/17
15:38
Hot Stocks
Breaking Hot Stocks news story on Bristol-Myers »

Bristol-Myers up 2.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

BMY

Bristol-Myers

$53.54

-1.05 (-1.92%)

15:38
02/21/17
02/21
15:38
02/21/17
15:38
Periodicals
Carl Icahn takes stake in Bristol-Myers, WSJ reports »

Icahn sees value in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

DEPO

Depomed

$16.47

-0.38 (-2.26%)

15:35
02/21/17
02/21
15:35
02/21/17
15:35
Options
Depomed options imply 6.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

CSCO

Cisco

$33.74

0.14 (0.42%)

15:32
02/21/17
02/21
15:32
02/21/17
15:32
Conference/Events
Cisco to host service provider tech talk »

Cisco SVP Kanouff hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

EFA

iShares MSCI EAFE Index Fund

$60.65

0.15 (0.25%)

15:31
02/21/17
02/21
15:31
02/21/17
15:31
Options
Defensive option play opened in the iShares MSCI EAFE Fund »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$16.96

0.1 (0.59%)

15:26
02/21/17
02/21
15:26
02/21/17
15:26
Options
Nuance call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRBP

Corbus Pharmaceuticals

$8.85

0.55 (6.63%)

15:25
02/21/17
02/21
15:25
02/21/17
15:25
Conference/Events
Cantor Fitzgerald health/pharma analysts hold analyst/industry conference call »

Analysts, along with Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

$NSD

NASDAQ Market Internals

15:21
02/21/17
02/21
15:21
02/21/17
15:21
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:21
02/21/17
02/21
15:21
02/21/17
15:21
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENT

Global Eagle

$6.22

-0.01 (-0.16%)

15:21
02/21/17
02/21
15:21
02/21/17
15:21
Downgrade
Global Eagle rating change  »

Global Eagle downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

ARLZ

Aralez

$4.50

-0.02 (-0.44%)

, AMGN

Amgen

$173.29

1.18 (0.69%)

15:20
02/21/17
02/21
15:20
02/21/17
15:20
Hot Stocks
Bass group fails to prove Aralez patent claims unpatentable »

The Coalition For…

ARLZ

Aralez

$4.50

-0.02 (-0.44%)

AMGN

Amgen

$173.29

1.18 (0.69%)

BIIB

Biogen

$288.94

-1.19 (-0.41%)

ABBV

AbbVie

$61.66

-0.1147 (-0.19%)

JNJ

Johnson & Johnson

$119.49

0.63 (0.53%)

SHPG

Shire

$181.08

2.38 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 24

    Feb

  • 06

    Mar

  • 07

    Mar

  • 09

    Mar

  • 14

    Mar

  • 17

    Mar

  • 21

    Mar

  • 27

    Mar

  • 01

    Apr

  • 26

    Jun

  • 19

    Jul

HCLP

Hi-Crush Partners

$21.58

0.275 (1.29%)

15:20
02/21/17
02/21
15:20
02/21/17
15:20
Options
Hi Crush options imply 9.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

TWTR

Twitter

$16.42

-0.2 (-1.20%)

15:18
02/21/17
02/21
15:18
02/21/17
15:18
Hot Stocks
Twitter head of entertainment talent resigns »

Lara Cohen, head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

KRP

Kimbell Royalty Partners

$19.90

0.15 (0.76%)

15:16
02/21/17
02/21
15:16
02/21/17
15:16
Hot Stocks
Breaking Hot Stocks news story on Kimbell Royalty Partners »

Rivercrest Royalties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GT

Goodyear Tire

$36.07

-0.09 (-0.25%)

15:16
02/21/17
02/21
15:16
02/21/17
15:16
Options
Goodyear Tire put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$20.11

-0.06 (-0.30%)

15:16
02/21/17
02/21
15:16
02/21/17
15:16
Conference/Events
Barrick Gold to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

MARA

Marathon Patent Group

$1.34

-0.04 (-2.90%)

, HON

Honeywell

$124.79

0.2317 (0.19%)

15:15
02/21/17
02/21
15:15
02/21/17
15:15
Hot Stocks
Marathon Patent unit files patent infringement suits against Honeywell, Somfy »

Marathon Patent Group…

MARA

Marathon Patent Group

$1.34

-0.04 (-2.90%)

HON

Honeywell

$124.79

0.2317 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 01

    Mar

  • 29

    Mar

  • 24

    Apr

15:15
02/21/17
02/21
15:15
02/21/17
15:15
General news
Breaking General news story  »

San Francisco Federal…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.